7-Azaindole Compounds Targeting ActRIIB in Cancer Cachexia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer cachexia, particularly those targeting the myostatin-related pathways, are limited to large molecule drugs that face research difficulties and high costs, necessitating the development of small molecule inhibitors for more effective and affordable therapies.
Innovation Solution
Development of novel 7-azaindole compounds containing pyrazole or indole substituents that inhibit the ActRIIB receptor, offering a potential alternative to protein or gene drugs by providing a small molecule solution for cancer cachexia treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large molecule drugs (antibody inhibitors, recombinant fusion proteins) are used to target ActRIIB receptor, then the inhibitory effect on myostatin signaling is improved, but the research difficulty and cost increase significantly
Solution Approach 1:
The patent changes the molecular size parameter from large molecule (protein/gene drugs) to small molecule (7-azaindole compounds with molecular weight around 300-500 Da). This parameter change maintains the ActRIIB inhibitory function while dramatically reducing research difficulty and development cost, as small molecules are easier to synthesize, optimize, and manufacture at scale compared to biologic therapies.
2Reliability
If protein or gene drugs are developed for cancer cachexia treatment, then the therapeutic effect is improved, but the application in clinical treatment becomes difficult due to high cost and complexity
Solution Approach 1:
The patent employs small molecule compounds that can be manufactured cost-effectively at scale compared to expensive biologic therapies. These small molecule 7-azaindole compounds represent a more economical alternative that maintains therapeutic efficacy while enabling broader clinical accessibility and easier manufacturing processes, including potential oral administration routes.
3Device complexity
If small molecule inhibitors are developed instead of large molecule drugs, then the cost and research difficulty are reduced, but the development of effective compounds becomes more challenging
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (pyrazole or indole substituents at the 7-position of the azaindole core) that locally enhance binding affinity to ActRIIB. This localized structural optimization allows the small molecule to achieve potent inhibition despite the inherent challenges of designing effective small molecule inhibitors, thereby resolving the contradiction between reduced complexity and development challenge.
Data Source
Figure 1~12
Figure 13~27
Figure 28~34
AI summary
Disclosed in the present invention are 7-azaindole compounds, a preparation method therefor, and the use thereof, belonging to the field of drug synthesis. The present invention particularly relates to 7-azaindole compounds containing pyrazole or indole substitution represented by general formula (I), a preparation method therefor and the use thereof in medicine. The compounds of the present invention alleviate cancer cachexia skeletal muscle atrophy by means of inhibiting ActRIIB protein in the MSTN pathway, thereby achieving a remarkable anti-cancer-cachexia effect. Experimental results show that the compounds have good anti-cachexia activity and thus can be further used for preparing novel anti-cachexia drugs.